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Abstract: Objective: Bisphosphonate-related osteonecrosis of the jaws is considered to be a rare but
severe complication of bisphosphonate therapy. To understand this condition better, data collection
is essential. Although the number of scientific papers about this subject is large, to date only a few
multicenter reports have been published. Study design: We present a novel cloud-based data
collection system for the evaluation of the risk factors of bisphosphonate-related osteonecrosis of
the jaws. Web-based questionnaire and database have been set up and made available to voluntary
researchers and clinicians in oral and maxillofacial surgery in Hungary and Slovakia. Results: To
date, fifteen colleagues from eight maxillofacial units have joined the study. Data of 180 patients have
been recorded. Collected data were statistically analysed and evaluated from an epidemiological
point of view. Conclusions: Authors consider cloud-based multicenter data collection a useful tool
that allows for real-time collaboration between users, facilitates fast data entry and analysis, and
thus considerably contributes to widening our knowledge of bisphosphonate-related osteonecrosis of
the jaws.
Keywords: bisphosphonate; osteonecrosis of jaws; cloud-based; data collection; multicenter
1. Introduction
Bisphosphonate-related osteonecrosis of the jaws (BRONJ) was first reported in 2003 by Marx [1].
The signs and symptoms of this condition are broad and include, amongst others, exposed and necrotic
bone that is isolated to the jaw; pain; tooth mobility; mucosal swelling; erythema; and ulceration [2–4].
To distinguish BRONJ from other delayed healing conditions, in 2007 the following definition was
suggested by the American Association of Oral and Maxillofacial Surgeons: ‘’patients may be considered
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to have BRONJ if all of the following three characteristics are present: current or previous treatment
with a bisphosphonate; exposed bone in the maxillofacial region that has persisted for more than eight
weeks; and no history of radiation therapy to the jaws” [5].
In 2014, the revised AAOMS Position Paper recommended changing the nomenclature of BRONJ
to MRONJ (medication-related osteonecrosis of the jaw), and the working definition of this condition
was modified to accommodate the growing number of osteonecrosis cases associated with other
antiresorptive (denosumab) and antiangiogenic therapies (Table 1) [6].
Table 1. Changes in the nomenclature and definition of bisphosphonate/medication related osteonecrosis
of the jaws.
Definition of Bisphosphonate-Related
Osteonecrosis of the Jaws (BRONJ) (AAOMS 2009) Definition of MRONJ (AAOMS 2014)
1. Current or previous treatment with a
bisphosphonate;
2. Exposed bone in the maxillofacial region that has
persisted for more than eight weeks;
3. No history of radiation therapy to the jaws.
1. Current or previous treatment with antiresorptive
or antiangiogenic agents;
2. Exposed bone or bone that can be probed through
an intraoral or extraoral fistula(e) in the maxillofacial
region that has persisted for more than eight weeks;
3. No history of radiation therapy to the jaws or
obvious metastatic disease to the jaws.
(AAOMS—American Association of Oral and Maxillofacial Surgeons; MRONJ—medication related osteonecrosis of
the jaw).
The present study had been commenced before these modifications were published; therefore, in
this paper nomenclature from the 2009 AAOMS Position Paper are used [7]. The pathophysiology of
BRONJ is not completely clarified; several pathways are suggested that could elucidate the unique
localization of the disease, including inflammation, infection, microtrauma, altered bone remodeling,
soft tissue toxicity, and angiogenesis inhibition [8–13].
Most authors agree that expanding our current knowledge is the basis for effective prevention
and therapeutic strategies [14–16]. The literature on BRONJ is enormous and growing, but most of
these papers are case presentations or reports on a small series of patients. Data are not statistically
significant in most of these studies due to the low number of patients included [17–20].
The number of subjects treated in a single maxillofacial or dental unit is likely insufficient to
draw statistically significant conclusions. Although there are some large patient cohorts in this field,
most of these have had methodological limitations, including the lack of standardized case definitions,
the absence of information on patients characteristics, and the scarcity of comparable data [21–28].
Recently, some single-institution studies with a large number of patients have been published in this
field [29–32]. The aim of our study was to create a multicenter data collection system that would
gather demographic, clinical, and pharmacological data of a large number of patients suffering from
BRONJ [33–41].
A cloud database allows for real-time collaboration between several users, and thus it considerably
contributes to fast data entry, processing, and analysis. It eliminates the difficulties of traditional
information transfer. Although this technology has been around for several years, it has not gained
popularity in medical demographic studies [42] (Table 2).
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Table 2. Advantages of spreadsheet-based questionnaires.
1. Easy to use/apply for simple users;
2. Allow for easy collaboration regardless of distance;
3. (Common) database eliminates duplicate information;
4. Increase efficiency and data consistency;
5. Automatic backup prevents accidental data loss;
6. Data integrity and portability are assured between platforms;
7. Control access permissions and user restrictions;
8. Easy retrieval and updating of data;
9. Only the bandwidth of the network limits the speed of data transmission;
10. Information security;
11. The user’s interface can easily be adapted to the needs of the survey.
2. Materials and Methods
In 2012, following the approval of the local Scientific and Research Ethics Committee of the
Medical Research Council, an online spreadsheet-based questionnaire was set up.
The questionnaire has been made available to cooperating maxillofacial units for nonprofit
use. The participation has been voluntary. Data have been collected on gender, age on onset of the
osteonecrosis, underlying and concomitant diseases, dental history, type of bisphosphonate taken,
duration, frequency and route of administration, presumed trigger factors (e.g., tooth extraction,
implant placement, periodontal surgery), clinical stage, location, and extent of lesions.
The inclusion criteria of the study were determined as follows:
(1) Previous or current BP treatment regardless of drug type, dose, or route of administration;
(2) Consecutive or concomitant BP treatment with different bisphosphonate agents;
(3) Intra- or extraoral lesion following or after bisphosphonate therapy.
Patients receiving bisphosphonate treatment but without symptoms were not included in the
study. Osteonecrosis cases associated with consecutive and/or concomitant combined antiresorptive
and antiangiogenic therapies were not taken into consideration in this study. Patients with previous
or undergoing radiation therapy of head and neck region have been excluded. Originally, staging
was determined according to the Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaw
published by the American Association of Oral and Maxillofacial Surgeons in 2009 but later it was
modified according to the 2014 AAOMS’s update [6,7].
A detailed dental and medical history was recorded with regard to previous and current chronic
diseases. Clarification of triggering factors during the development of osteonecrosis has received
special attention during retrospective data collection. To determine the location and extent of the
osteonecrotic lesions both jaws were divided into five regions (RM: right molar, RP: right premolar, Fr:
frontal, LP: left premolar, and LM: left molar). If more than one regions were affected by the necrosis,
each were taken into consideration.
Statistical analysis was performed with Statistical Program for Social Sciences version 23.0 for
Windows (SPSS, Chicago, IL, USA). A p-value of less than 0.05 was interpreted to imply statistical
significance. Means and standard deviations (SD) were calculated. Unpaired student’s t-test was used
for evaluation of statistical significance.
3. Results
To date, seven maxillofacial units from Hungary and one from Slovakia have joined the study.
Altogether, 15 colleagues participated in the data collection. The data of 180 BRONJ cases have been
recorded. The number of reported cases decreased from year to year 64 patients, 41 patients, 34 patients,
23 patients, and 18 patients, respectively.
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Full data were obtained for 148 (82.2%) patients. In 32 cases (17.8%), data collection was incomplete.
The data on age, sex, underlying disease, method of drug administration, and staging were complete
in all cases. All data were included in the statistical analysis.
3.1. Sex Ratio
There was a female predominance with 58 men (32.2%) and 122 women (67.8%) affected.
Male-to-female ratio was 1:2.1; this correlates well with other results (Table 3) [18,19,23,28,34].
Table 3. Male–female ratio by different authors.
Number Female Male
Vereb et al. 180 122 67.8% 58 32.2%
Otto 2012 126 92 73.0% 34 27.0%
Diniz-Freitas 2012 20 19 95% 1 5%
Schubert 2011 258 175 67.8% 83 32.2%
Kos 2010 34 19 55.9% 15 44.1%
Mavrokokki 2007 114 63 55% 51 45%
Summary 732 490 66.9% 242 33.1%
3.2. Underlying Disease
The vast majority of BRONJ cases occurred in patients with malignant diseases (n = 140; 77.8%).
Thirty four patients (18.9%) received bisphosphonate for osteoporosis; two patients (1.1%) were
diagnosed with rheumatoid arthritis. In four cases (2.2%), the reasons for treatment remained unknown
because of the nature of retrospective studies (Table 4).
Table 4. Age distribution based on known underlying disease (n = 176).
Underlying Disease n Mean Min Max SD
Malignant
Breast cc. 66 64.68 37 85 10.16
Prostate cc. 30 71.57 61 89 7.00
Multiple myeloma 16 67.62 57 80 6.09
Renal cc. 13 62.92 51 77 8.45
Lung cc. 7 65.00 48 81 10.77
Gastrointestinal cc. 5 66.80 54 80 –
Other 3 62.00 53 75 –
Total malignant 140 66.32 37 89 9.43
Benign
Osteoporosis 34 70.31 42 84 9.79
Rheumatoid arthritis 2 39 38 40 –
Total benign 36 68.57 38 84 –
Summary 176 66.80 37 89 –
3.3. Age
The mean age at the time of the diagnosis was 66.80 years, 66.22 years in women (range 37–85 years;
SD 10.29 years), and 68.02 years in men (range 42–89 years; SD 9.33 years). There was no significant
difference between the ages of males and females (p = 0.246). Patients suffering from nonmalignant
diseases (osteoporosis, rheumatoid arthritis) were generally older (n = 36; mean 68.57 years; range
38–84 years, SD 9.79 years) than patients with malignant disease (n = 140; mean 66.32 years; range
37–89 years, SD 9.43 years).
Within the malignant group renal cancer patients were generally younger (n= 13; mean 62.92 years;
range 51–77 years, SD 8.45 years) than the rest of the group (n= 127; mean 66.67 years; range 37–89 years,
SD 9.49 years), but the difference was not significant (p = 0.153). Breast cancer patients were only
slightly younger (n = 66; mean 64.68 years; range 37–85 years, SD 10.16 years), but the age difference
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was statistically significant (p = 0.045) when compared with the rest of the group (n = 74; mean
67.86 years; range 48–89 years, SD 8.49 years). The mean ages of multiple myeloma and lung cancer
patients were 67.62 (n = 16; range 57–80 years, SD 6.9 years) and 65.00 (n = 7; range 48–81 years,
SD 10.77 years), respectively. Prostate cancer patients (n = 30; mean 71.57 years; range 61–89 years,
SD 7.00 years) were significantly older (p = 0.000075) than the other malignant cases (n = 110; mean
64.93 years; range 37–85 years, SD 9.53 years) (Table 4).
3.4. Comorbidity
Comorbidity data were complete in 162 (90%) cases. High blood pressure and/or cardiac disease
was reported in 75 (46.29%) cases. Nineteen (11.72%) patients suffered from diabetes. Chronic
obstructive pulmonary disease (COPD) and/or asthma were diagnosed in 6 (3.70%) cases. Concomitant
renal, hepatic, and gastrointestinal diseases were reported in 11 (6.79%), 7 (4.32%), and 9 (5.56%)
patients, respectively.
3.5. Route of Administration and Type of Bisphosphonate
Fifty-two individuals (28.9%) were given oral bisphosphonates alone. In this group, ibandronic
acid (n = 19; 36.6%) and alendronic acid (n = 18; 34.6%) were the most frequently used agents, followed
by clodronic acid (n = 9; 17.3%) and risedronic acid (n = 6; 11.5%) (Table 5).
Table 5. BRONJ cases caused by oral bisphosphonates.
Oral Bisphosphonate Benign Diseases Malignant Diseases Summary
aledronate 17 1 18
ibadronate 2 17 19
clodronate 4 5 9
risedronate 6 – 6
Summary 29 23 52
In vast majority of the cases, bisphosphonates were administered intravenously alone (n = 106;
58.9%) or in combination with oral drugs (n = 22; 12.2%). A total of 128 patients (71.1%) received
intravenous bisphosphonate therapy. Intravenous zoledronic acid was associated with the highest risk
of BRONJ, and 110 patients (61.1%) were treated with this drug alone or in combination with other
agents (n = 6; 3.3%). Altogether, 116 patients (64.4% of all patients; 90.6% in the intravenously treated
group) were administered intravenous zoledronic acid. (Table 6)
Table 6. Development of osteonecrosis depending on the type of intravenous bisphosphonate and the
number of infusions administered.
Number of
Bisphosphonate Infusions
Zoledronate
(Combined)
Zoledronate
(Single) Ibandronate Pamidronate
1–6 x – 29 – –
7–12 x 1 17 5 –
13–18 x – 11 1 –
19–24 x 3 12 3 –
25–30 x 1 6 1 –
31–36 x – 7 – –
37–42 x – 2 – –
43–48 x – 6 1 –
>48 x 1 20 – 1
Summary 6 110 11 1
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Results of the Pearson Chi-square test showed a statistically significant relationship (p = 0.023)
between the severity of stages (Stage 1: mild versus Stage 2+3: serious) and the administration method
(Table 7.)
Table 7. The correlation between the severity of osteonecrosis of the jaws (ONJ) and the route
of administration.
Staging Total
Stage 1 Stage 2 Stage 3
Intravenous
14 57 35 106
13.2% 53.8% 33.0% 100.0%
Both
7 11 4 22
31.8% 50.0% 18.2% 100.0%
Oral
15 28 9 52
28.8% 53.8% 17.3% 100.0%
Total
36 96 48 180
20.0% 53.3% 26.7% 100.0%
3.6. Presumed Triggering Factors
Presumed triggering factors were reported in 167 cases. Dental extraction was the most common
predisposing event (n = 121; 72.4%). A further six patients (3.6%) had previous dentoalveolar surgery
(implant placement, periodontal surgery). Pre-existing inflammatory diseases such as periodontal
and/or periapical pathology were present in 19 cases (11.4%). Denture use was thought to be the main
trigger factor in 12 cases (7.2%). BRONJ was considered of spontaneous origin in nine cases (5.4%).
3.7. Localization of the Osteonecrosis
BRONJ was observed altogether in 194 jaws. In 124 patients (68.9%), only the mandible; in
42 patients (23.3%), only the maxilla; and in 14 cases (7.8%), both jaws, were affected.
Altogether, 304 regions were affected by BRONJ in 180 patients, 213 regions (70.1%) in the
mandible, and 91 regions (29.9%) in the maxilla. The most common sites of osteonecrosis were the
molar (n = 98; 32.2%) and the premolar regions of the mandible (n = 82; 27%), followed by the upper
molar (n = 36; 11.8%) and premolar regions (n = 35; 11.5%). The lower and upper front regions were
affected in 33 (10.9%) and 20 (6.6%) cases, respectively (Figure 1).
3.8. Staging
At the time of the first clinical examination, 36 cases (20.0%) were categorized as stage 1.
The majority of the patients (n = 96; 53.3%) were diagnosed as stage 2. Forty-eight cases (26.7%) were
classified as stage 3 with extraoral fistula; pathological fracture; and involvement of the maxillary
sinus, the inferior border, or the ramus of the mandible. The underlying disease and its malignant or
benign nature were determined in 176 cases. There were 36 benign cases; the distributions of stages
were as follows: stage 1: 36.1% (n = 13), stage 2: 47.2% (n = 17), and stage 3 16.7% (n = 6), respectively.
From the 140 underlying malignancies, 23 (16.4%) were classified in stage 1, 77 cases (55.0%) ranked
as stage 2, and 40 cases (28.6%) belonged to stage 3. At the time of the first visit, more severe stages
(2–3) occured in a higher proportion of patients with malignancies than among patients with benign
conditions (stage 1: 36.1% vs. 16.4%, stage 2: 47.2% vs. 55.0%, stage 3: 16.7% vs. 28.6%). As stage
worsened, the proportion of malignant cases increased significantly compared to the number of benign
cases (stage 1—1:1.77, stage 2—1:4.53, and stage 3—1:6.66) A significant difference was found between
the benign and malignant groups (Pearson Chi-Square test p = 0.026). Although much more women
than men are affected by BRONJ, in stage 3 the numbers of female and male patients were almost equal
(26 (54.2%) and 22 (45.8%), respectively).
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left molar).
4. Discussion
BRONJ is a relatively newly recognized condition that has generated great interest not only
amongs oral and maxillofacial surgeons but also in other medical and research communi ies.
Our study found female predominanc amon BRONJ pa ients (female 67.8%, male: 32.2 ; mal
to female ratio 1:2.1), hich is in line with the results of Otto and Schubert [23,34] but slightly h gher
than in Kos’ and Mavrok kki’s publications [18,28]. Female-to-male ratio of 8:1 was published by
Paz a as in 2007 [35].
77.8% f the patients suffered from n underlying malignant disease, a proportion that losely
correlated with Mavrokokki’s result, who referred to 72% of bone malignancies among their patients [28].
The mean age of the b nign group (68.57 years) is not significantly hig r than the age of the malignant
group (66.32 years). Within the malignant group, BRONJ developed at a si nifica ly higher a e
in prostate canc r patients compared to the remainder of the group. BRONJ was diagnosed at
a significantly younger age in breast can er patients compared to he rest of the malignant group.
Although in our investigation ther were only two rheumatoid arthritis pat ents (mean: 39.0 years SD:
1 years), re was still a surprisi gly huge age difference when it was compared to the res lts of Di
Fede ( = 18 ean: 68 years SD: 8 years) [17].
Gabbert’s examination pointed out that osteonecrosis-free survival in single bisphosphonate
users was significantly longer in pamidronate-treated patients than in zoledronate or ibandronate
users [27]. I our study, from the intravenous group 127 of 128 patients (99.2%) were administered
zoledronate and/or ibandronate and only one patient (0.8%) was diagnosed with BRONJ following
pamidronate treatment. Our results also prove that the route of administration has a significant
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(p = 0.023) association with the severity of the osteonecrosis. According to Thumbigere-Math et al.,
increased cumulative doses and long-term bisphosphonate treatment are the most important risk
factors for osteonecrosis, but the type of bisphosphonate may also play a role in the incidence of
osteonecrosis; our results confirm these findings [26].
According to the literature, the mandible is affected in 64 to 70.6%, and the maxilla is involved in
18.3 to 27%. BRONJ was present in both jaws in 9% to 11.1%. Our findings (mandible 70.1%, maxilla
23.3%, and both jaws 7.8%) correlate well with these results. There is a characteristic distribution of
osteonecrosis with a predilection for the molar and premolar region in both jaws, just as it was pointed
out by Otto et al. [28,34].
At the time of the diagnosis, the majority of the patients (53.3%) were categorized as stage 2; 20.0%
and 26.7% were classified as stage 1 and stage 3, respectively. These findings are similar to those of
Schiodt et al. (stage 1: 26%; stage 2: 58%; stage 3: 10%; unknown: 3%; resolved: 2%) [39]. Although
much more women than men are affected by BRONJ, their number in stage 3 is nearly the same (26
and 22, respectively). The ratio of malignant cases to benign cases increased significantly (p = 0.026) as
the stage worsened (stage 1—1:1.77, stage 2—1:4.53, and stage 3—1:6.66).
The evolution of cloud-based information technology has dramatically changed data collection
and analysis for scientific purposes. To the best of our knowledge, our study is the first one that has
collected data on BRONJ patients from multiple centers with this method.
Despite the many advantages offered by cloud-based technology, our study also has some pitfalls.
Participation was voluntary, and this probably resulted in under-reporting; therefore, our data are
not informative about the incidence of BRONJ. The relatively high number of incomplete reports is
surprising, but this can be explained by the fact that the online questionnaire was not filled out at the
time of the patient’s examination and later data were not found in the documents. The number of
patients reported in this study is high compared to other single-center or even multicenter studies, but
the average number of patients reported per center per year is less than six in the 4-year study period.
The decreasing trend of the number of new patients reported per year probably reflects that
voluntary researchers have lost their initial enthusiasm, but better patient management, early diagnosis,
and state-of-the-art prevention techniques might also have played an important role. A sample size of
180 BRONJ cases is considered statistically significant, but data were not always sufficient to reach
statistically reliable conclusions when the patients were classified into groups. More patients are
needed to improve power of the study. A multicenter registry that collects systematic information
on epidemiological data is essential to increase our knowledge of BRONJ. Cloud-based information
collection is an ideal tool for this purpose. The online and voluntary nature of the current study
may slightly diminish the accuracy of the results, but the increasing number of patients involved
will improve statistical conclusions. The data collection is ongoing to improve the scientific value of
the study.
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